Another possible cause of rosacea is the increased presence of a common microscopic mite called Demodex folliculorum. This mite is more abundant on the skin of people with rosacea. According to ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Dabbing trouble spots with diluted tea tree oil helps eradicate microscopic demodex mites that trigger rosacea's red bumps and pustules. A study in the Journal of Cosmetic Dermatology found that a ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

A Phase II study for ocular rosacea is set to begin in late 2025, with data expected in 2026. Tarsus aims to expand physician education to identify Demodex blepharitis in broader patient categories.

IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27 th Annual Global ...

XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular ...